98%
921
2 minutes
20
Background: The cardiometabolic index (CMI) is a reliable marker used to assess the degree of obesity and lipid metabolism disorders in individuals. Emerging evidence indicates that disorders of lipid metabolism and sarcopenia share a common pathophysiologic basis. However, few studies have investigated the association between CMI and sarcopenia. Therefore, this study aimed to find the possible correlation between CMI and sarcopenia.
Methods: This study used cross-sectional research methods to investigate data on CMI, sarcopenia, and other covariates among participants in the National Health and Nutrition Examination Survey (NHANES) from 2011 to 2018. We explored the relationship between CMI and sarcopenia through multivariate linear and logistic regression, and we performed sensitivity and subgroup analyses. Also, receiver operating characteristic (ROC) curve analysis and area under the curve (AUC) were utilized to evaluate the performance of CMI in identifying sarcopenia.
Results: Of the 4,808 adults aged 20 to 59 included in this study, 428 (8.90 %) were identified as having sarcopenia. A significant nonlinear association between CMI and sarcopenia was demonstrated in a generalized additive model (GAM). After inclusion of all covariates, CMI showed a significant association with the prevalence of sarcopenia (OR = 1.173(1.086-1.267), < 0.001). CMI got an AUC of 0.69 in identifying sarcopenia. Finally, subgroup analyses showed that the association between CMI and sarcopenia was particularly pronounced in individuals who differed in marital status, poverty-to-income ratio, alcohol consumption, patients without diabetes, and patients with hypertension ( < 0.05).
Conclusion: This study demonstrated that an elevated CMI was associated with an increased prevalence of sarcopenia. The finding suggests that CMI could serve as a potential marker for sarcopenia, highlighting the need for further research to explore the relationship between dyslipidemia and sarcopenia.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12398217 | PMC |
http://dx.doi.org/10.1016/j.jcte.2025.100415 | DOI Listing |
J Clin Transl Endocrinol
September 2025
School of Nursing, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310051, China.
Background: The cardiometabolic index (CMI) is a reliable marker used to assess the degree of obesity and lipid metabolism disorders in individuals. Emerging evidence indicates that disorders of lipid metabolism and sarcopenia share a common pathophysiologic basis. However, few studies have investigated the association between CMI and sarcopenia.
View Article and Find Full Text PDFSci Rep
July 2025
Department of Spine Surgery, Anhui No. 2 Provincial People's Hospital, No.1868 Dangshan Road, Yaohai District, Hefei, 230000, Anhui, China.
Although evidence suggests that lipid accumulation product (LAP) and cardiometabolic index (CMI) may be associated with the pathogenesis of sarcopenia, their relationship remains unclear. This study aims to investigate their association with sarcopenia. This cross-sectional study analyzed data from 4,172 adults aged 20-59 years from the NHANES 2011-2018 cycles.
View Article and Find Full Text PDFActa Diabetol
June 2025
Yuquan Hospital, Tsinghua University, Beijing, 100040, China.
Aims: This study aimed to explore the relationships between lipid metabolism indices-the Lipid Accumulation Product (LAP), Visceral Adiposity Index (VAI), Cardiac Metabolic Index (CMI), and Atherogenic Index of Plasma (AIP)-and sarcopenia in individuals aged ≥ 60 years, and to investigate the mediating role of uric acid (UA) in these relationships. The goal was to provide scientific evidence and practical guidance for preventing and treating sarcopenia in older adults.
Methods: Data from 2001 participants aged ≥ 60 years in the 2003-2006 National Health and Nutrition Examination Survey (NHANES) were analyzed.
PLoS One
May 2025
Department of Clinical Nutrition, Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
Background: The cardiometabolic index (CMI), initially devised as a diagnostic tool for diabetes mellitus, has evolved into a composite biomarker for evaluating metabolic syndrome and cardiovascular disease risk. In order to shed light on any possible interactions between sarcopenia and CMI, this study will look at the relationship between the two.
Methods And Results: Data from the 2011-2018 National Health and Nutrition Examination Survey (NHANES) were analyzed to investigate the possible link between sarcopenia and CMI.
BMC Public Health
April 2025
Department of Anesthesiology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, No.55, Section 4, South Renmin Road, Chengdu, China.
Background: The association between sarcopenia and cardiometabolic index (CMI) among the Chinese elderly adults remains unclear. The present study aimed to examine the association based on a national survey.
Methods: Data from China Health and Retirement Longitudinal Study (CHARLS, wave 2011 and 2015) were employed.